S. D. Richman, M. T. Seymour, P. Chambers, et al., “KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated with Poor Prognosis but Do Not Preclude Benefit from Oxaliplatin or Irinotecan: Results from the MRC FOCUS Trial,” Journal of Clinical Oncology, Vol. 27, No. 35, 2009, pp. 5931-5937. doi:10.1200/JCO.2009.22.4295

has been cited by the following article:

• TITLE: Molecular Markers for the Prediction of Anti-EGFR Monoclonal Antibody Treatment Efficacy in Metastatic Colorectal Cancer

  AUTHORS: Cheng-Bo Han, Jie-Tao Ma, Fan Li, Hua-Wei Zou

  KEYWORDS: Molecular Marker, Epidermal Growth Factor Receptor, Kras, EGFR Monoclonal Antibody, Metastatic Colorectal Cancer

  JOURNAL NAME: Journal of Cancer Therapy, Vol.2 No.5, December 31, 2011

  ABSTRACT: The implementation of individualized targeted therapy for metastatic colorectal cancer (mCRC), in addition to standard chemotherapeutic regimens, currently is a topic under debate. Approximately 35% - 45% of mCRC patients exhibit mutated KRAS, which is considered to be an independent predictor of poor response to treatment with epidermal growth factor receptor (EGFR) monoclonal antibody. However, only about 50% of patients with wild-type KRAS respond to anti-EGFR therapy. Two major EGFR-dependent signaling pathways, RAS-RAF-MAPK and PI3K-PTEN-AKT, may be involved in the poor response to anti-EGFR. Increased EGFR gene copy number as detected by fluorescence in situ hybridization, but not increased EGFR protein expression, correlates with efficacy of anti-EGFR treatment. The identification of mutations in BRAF and PIK3CA (exon 20) and deletions in PTEN also may help clinicians screen for anti-EGFR resistance in mCRC patients with wild-type KRAS. To guide health professionals through the realm of individualized targeted therapies for mCRC, we review recent progress on identifying negative predictors and prognostic markers of anti-EGFR treatment efficacy.